2023-09-07 08:25:18 ET
More on Alnylam, Roche, etc.
- Alnylam: Unlimited Promise Or Unlimited Losses?
- Alnylam Pharmaceuticals, Inc. 2023 Q2 - Results - Earnings Call Presentation
- Alnylam Pharmaceuticals, Inc. ( ALNY ) Q2 2023 Earnings Call Transcript
- Roche: FX Drug But Positive Outlook
- Alnylam: Zilebesiran Deal With Roche Reveals A Very Long Development Timeline
- Roche Holding AG ( OTCQX:RHHBY ) Q2 2023 Earnings Call Transcript
- Alnylam picked for positive catalyst watch at Citi on amyloidosis therapy.
- Roche granted U.K. approval for subcutaneous Tecentriq
- Alnylam appealing patent ruling in case against Moderna
- Roche sends anti-TIGIT developers higher after cancer drug data (update)
- Roche Holding Non-GAAP EPS of CHF10.10, revenue of CHF29.78B
- Roche, Alnylam in pact for blood pressure candidate
- HSBC bullish on Roche, Lonza; bearish on Bristol-Myers, GSK, Moderna
- Roivant reportedly could sell colitis drug to Roche for over $7B
For further details see:
Alnylam succeeds in Phase 2 trial for blood pressure drug